Daniil Kirianov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniil Kirianov has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Birgit Engeland
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
2 shared publications - Dirk Isbrandt
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
2 shared publications - Konstantin Khodosevich
Biotech Research and Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Malte Stockebrand
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany
2 shared publications - Xianan Xie
Biotech Research and Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Constanza Bravo-Rossainz Baez
Department of Neurophysiology, Institute of Physiology, University of Tübingen, Tübingen, Germany
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1) , 212
Altered oligodendroglial cell development and increased myelination in SCN2A gain-of-function-linked epilepsy
Gain-of-function variants in SCN2A, encoding the voltage-gated sodium channel Na V 1.2, cause developmental and epileptic encephalopathies characterized by seizures, developmental delay, and white matter abnormalities. While Na V 1.2 is known to regulate neuronal excitability, its role in oligodendroglial cells is unclear. Here, we show that Na V 1.2 is expressed in early oligodendrocyte lineage stages. In mice carrying the gain-of-function Scn2a p.A263V variant, oligodendrocyte precursor cells displayed similar Na V 1.2 expression, but altered electrophysiological properties and calcium signaling. Single-cell transcriptomics revealed stage-specific changes in oligodendroglial maturation during early postnatal development, associated with lower variability and slightly faster conduction velocities. In adult mutant mice, gray matter myelination was increased without changes in oligodendrocyte numbers or myelin structure. Since Na V 1.2 was absent from mature oligodendrocytes, the enhanced myelination likely reflects an activity-dependent adaptation to altered neuronal network activity rather than a primary myelinopathy. These findings identify a glial contribution to SCN2A -related disease mechanisms and underscore the need to consider neuron–glia interactions when developing targeted therapies for epilepsy.
- 7 October 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1) , 212
Open AccessAltered oligodendroglial cell development and increased myelination in SCN2A gain-of-function-linked epilepsy
Gain-of-function variants in SCN2A, encoding the voltage-gated sodium channel Na V 1.2, cause developmental and epileptic encephalopathies characterized by seizures, developmental delay, and white matter abnormalities. While Na V 1.2 is known to regulate neuronal excitability, its role in oligodendroglial cells is unclear. Here, we show that Na V 1.2 is expressed in early oligodendrocyte lineage stages. In mice carrying the gain-of-function Scn2a p.A263V variant, oligodendrocyte precursor cells displayed similar Na V 1.2 expression, but altered electrophysiological properties and calcium signaling. Single-cell transcriptomics revealed stage-specific changes in oligodendroglial maturation during early postnatal development, associated with lower variability and slightly faster conduction velocities. In adult mutant mice, gray matter myelination was increased without changes in oligodendrocyte numbers or myelin structure. Since Na V 1.2 was absent from mature oligodendrocytes, the enhanced myelination likely reflects an activity-dependent adaptation to altered neuronal network activity rather than a primary myelinopathy. These findings identify a glial contribution to SCN2A -related disease mechanisms and underscore the need to consider neuron–glia interactions when developing targeted therapies for epilepsy.
- Open Access
Early postnatal CA3 hyperexcitability drives hippocampal development and epileptogenesis in SCN2A developmental and epileptic encephalopathy
Developmental and epileptic encephalopathies caused by pathogenic variants in SCN2A ( SCN2A -DEE), encoding the voltage-gated sodium channel Na v 1.2, present with early-life seizures, developmental delay, and increased mortality. Using a novel Scn2a p.A263V gain-of-function (GOF) mouse model, we demonstrate gene-dose and background-dependent phenotypes ranging from self-limited neonatal seizures to chronic epilepsy with high mortality. In vivo electrophysiology revealed hippocampal seizures as early as postnatal day 2.5, with CA3-driven gamma oscillations preceding seizure onset. CA3 and CA1 pyramidal neurons exhibited transient hyperexcitability during early postnatal development, resolving by P24-30. Single-cell RNA sequencing uncovered gene dose-dependent accelerated maturation of hippocampal networks, peaking at P7, alongside widespread transcriptional changes in excitatory and inhibitory neurons. In adulthood, persistent hippocampal network alterations emerged, marked by reduced mid-gamma oscillations and theta-gamma coupling. Our findings establish hippocampal CA3 hyperexcitability as an early driver of epileptogenesis in SCN2A -DEE and highlight it as a potential therapeutic target to mitigate disease progression.
Open AccessEarly postnatal CA3 hyperexcitability drives hippocampal development and epileptogenesis in SCN2A developmental and epileptic encephalopathy
Developmental and epileptic encephalopathies caused by pathogenic variants in SCN2A ( SCN2A -DEE), encoding the voltage-gated sodium channel Na v 1.2, present with early-life seizures, developmental delay, and increased mortality. Using a novel Scn2a p.A263V gain-of-function (GOF) mouse model, we demonstrate gene-dose and background-dependent phenotypes ranging from self-limited neonatal seizures to chronic epilepsy with high mortality. In vivo electrophysiology revealed hippocampal seizures as early as postnatal day 2.5, with CA3-driven gamma oscillations preceding seizure onset. CA3 and CA1 pyramidal neurons exhibited transient hyperexcitability during early postnatal development, resolving by P24-30. Single-cell RNA sequencing uncovered gene dose-dependent accelerated maturation of hippocampal networks, peaking at P7, alongside widespread transcriptional changes in excitatory and inhibitory neurons. In adulthood, persistent hippocampal network alterations emerged, marked by reduced mid-gamma oscillations and theta-gamma coupling. Our findings establish hippocampal CA3 hyperexcitability as an early driver of epileptogenesis in SCN2A -DEE and highlight it as a potential therapeutic target to mitigate disease progression.